GlassScriptPhysician profile
Cameron Trodello
NPI 1144717901
$3,812.32
in general payments reported to CMS, 2019-2025
22 companies · $743 in 2025
The $743 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $322 · 2021: $486 · 2022: $967 · 2023: $638 · 2024: $547 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,906 · Education: $15.27 · Travel and Lodging: $6.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,905.75 |
| Education | $15.27 |
| Travel and Lodging | $6.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $586.00 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| Genzyme Corporation | $467.69 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $465.91 | 2022-2024 | Libtayo, Dupixent |
| Incyte Corporation | $337.56 | 2022-2025 | Opzelura, Opzelura |
| Abbvie INC. | $325.37 | 2020-2022 | |
| Galderma Laboratories, L.P. | $300.07 | 2022-2023 | |
| Pfizer INC. | $209.68 | 2022-2025 | |
| Amgen INC. | $190.15 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $184.26 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $151.35 | 2023 | Tremfya, Remicade, Simponi Aria |
| Leo Pharma INC. | $110.32 | 2023-2025 | Adbry |
| Almirall LLC | $92.03 | 2022-2025 | Klisyri, Seysara |
| Revance Therapeutics, INC. | $42.68 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $37.30 | 2025 | |
| Mayne Pharma Commercial LLC | $33.11 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $32.57 | 2024 | Bimzelx |
| Epi Health, LLC | $32.21 | 2022 | |
| Organon LLC | $31.07 | 2025 | |
| Journey Medical Corporation | $23.05 | 2025 | |
| Botanix Sb INC | $20.99 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $18.17 | 2024 | Ycanth |
| Biofrontera INC. | $11.57 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Trodello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.